Partial
Partially Aligned
Patient Risk:
Low
Summary
Some factual/general statements about dantrolene appear consistent with the provided label excerpts, but several claims are either not supported by the provided prescribing information (notably non-label pricing/resource-source claims) or cannot be verified from the excerpts supplied.
Category Scores
Accurate Statements
Dantrolene is a muscle relaxant.
Label excerpts indicate dantrolene sodium has skeletal muscle effects (e.g., dissociates excitation-contraction coupling and causes relaxation), consistent with muscle relaxant description.
Dantrolene is used in conditions such as spasticity.
No explicit “spasticity” indication is present in the provided Revonto label excerpts; this appears potentially inconsistent with the supplied indication focus on malignant hyperthermia. LabelSupport therefore cannot be established from the excerpts.
Unsupported Statements
Dantrolene sodium pricing in India typically depends on the specific formulation (brand vs generic), strength, and pack size.
No pricing, India, or market information is contained in the provided FDA label excerpts.
Prices for medicines in India vary by brand/generic name, strength, and pack size.
No pricing/market information is contained in the provided FDA label excerpts.
Prices for medicines in India vary by whether the medicine is imported versus locally supplied.
No pricing/market information is contained in the provided FDA label excerpts.
DrugPatentWatch.com is mainly used for patent/exclusivity and drug landscape information, not real-time retail pricing.
The provided FDA label excerpts do not address DrugPatentWatch.com or retail pricing sources.
For pricing in India, retail pharmacy listings are usually the right source.
The provided FDA label excerpts do not provide guidance about where to obtain retail pricing.
Contradictions
Important Omissions
The claim evaluation set includes none of Revonto-specific safety/administration requirements (e.g., 'not a substitute for supportive measures', 'continuous rapid IV push', dosing limits, extravasation precautions, calcium channel blocker interaction) that are material to malignant hyperthermia crisis management.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported statements are about pricing and website/source use, not prescribing or safety. One general clinical statement ('spasticity') is not supported by the provided Revonto label excerpts but is not directly linked to how Revonto should be used in a crisis.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are unrelated to the FDA-approved label (pricing/website guidance) and are unsupported by the provided prescribing information; the 'spasticity' use claim is not supported by the supplied Revonto label excerpts.
Suggested Improvement
Limit claims to label-supported statements for Revonto (malignant hyperthermia crisis management and prophylaxis/attenuation in susceptible patients, including supportive measures, dosing/administration instructions, and key precautions/interactions). Remove pricing/resource-source statements not addressed in the label, and only state indications explicitly present in the label excerpts.